» Articles » PMID: 39402211

127aa Encoded by CircSpdyA Promotes FA Synthesis and NK Cell Repression in Breast Cancers

Overview
Specialty Cell Biology
Date 2024 Oct 14
PMID 39402211
Authors
Affiliations
Soon will be listed here.
Abstract

Lipid metabolism reprogram plays key roles in breast cancer tumorigenesis and immune escape. The underlying mechanism and potential regulator were barely investigated. We thus established an in vivo tumorigenesis model, mice-bearing breast cancer cells were treated with an ordinary diet and high-fat diet, species were collected and subjected to circRNA sequence to scan the potential circRNAs regulating the lipid metabolism. CircSpdyA was one of the most upregulated circRNAs and had the potential to encode a 127-aa micro peptide (referred to as 127aa). 127 aa promotes tumorigenesis through promoting the fatty acid de novo synthesis by directly binding to FASN. Single-cell sequence indicated 127aa inhibited NK cell infiltration and function. This was achieved by inhibiting the transcription of NK cell activators epigenetically. Moreover, lipid-laden from 127aa positive cancer cells transferred to NK cells inhibited the cytotoxicity. Taken together, circSpdyA encoded 127aa promotes fatty acid de novo synthesis through directly binding with FASN and induced NK cell repression by inhibiting the transcription of NK cell activators.

Citing Articles

Effects of circulating RNAs on tumor metabolism in lung cancer (Review).

Zhao P, Zhu Z, Zheng X, Song Y, Chen C, Xu G Oncol Lett. 2025; 29(4):204.

PMID: 40070786 PMC: 11894507. DOI: 10.3892/ol.2025.14950.

References
1.
Jiang Y, Ma D, Suo C, Shi J, Xue M, Hu X . Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies. Cancer Cell. 2019; 35(3):428-440.e5. DOI: 10.1016/j.ccell.2019.02.001. View

2.
Gong Y, Ji P, Yang Y, Xie S, Yu T, Xiao Y . Metabolic-Pathway-Based Subtyping of Triple-Negative Breast Cancer Reveals Potential Therapeutic Targets. Cell Metab. 2020; 33(1):51-64.e9. DOI: 10.1016/j.cmet.2020.10.012. View

3.
Jin H, Wang J, Wang Z, Xi M, Xia B, Deng K . Lipid metabolic reprogramming in tumor microenvironment: from mechanisms to therapeutics. J Hematol Oncol. 2023; 16(1):103. PMC: 10498649. DOI: 10.1186/s13045-023-01498-2. View

4.
Xiao Y, Ma D, Yang Y, Yang F, Ding J, Gong Y . Comprehensive metabolomics expands precision medicine for triple-negative breast cancer. Cell Res. 2022; 32(5):477-490. PMC: 9061756. DOI: 10.1038/s41422-022-00614-0. View

5.
Yang F, Xiao Y, Ding J, Jin X, Ma D, Li D . Ferroptosis heterogeneity in triple-negative breast cancer reveals an innovative immunotherapy combination strategy. Cell Metab. 2022; 35(1):84-100.e8. DOI: 10.1016/j.cmet.2022.09.021. View